On this in-person episode of The Gut Onc Lab podcast, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome world-renowned BRCA specialist Dr. Kim Reiss to dismantle the historic view of pancreatic cancer as a monolithic, chemo-only disease. The group dives deep into the 5% to 9% of pancreatic ductal adenocarcinoma (PDAC) patients harboring germline or somatic homologous recombination repair (HRR) defects and how to maximize their survival.
Key discussion points include:
- First-Line Crosscurrents: Why the team remains FOLFIRINOX traditionalists over the newly approved NAPOLI-3 Nalirifox regimen, and the operational reality that universal testing must start at day zero.
- The APOLLO Trial Blueprint: Dr. Reiss details the international Phase III ECOG-ACRIN EA2192 trial—mirroring breast cancer’s landmark Olympia study—bringing a year of adjuvant olaparib maintenance into the curative-intent space.
- Brainwashing Fellows & Hunting Rare Variants: Raw advice for junior investigators on leveraging advocacy groups, social media, and temporal NGS tracking to keep specialized clinical trials accruing.
- The BRCA1 vs. BRCA2 Paradox: Dissecting Dr. Talia Golan’s Cancer Discovery data revealing why 50% of BRCA1 pancreatic tumors are actually sporadic bystander events, compared to the 90% true biallelic loss seen in BRCA2.
- Dismantling Negative Data: A critical look at SWOG 2001 and the European durvalumab/olaparib updates, explaining why adding immunotherapy to PARP inhibitors failed broadly across all-comers unless a specific T-cell inflamed microenvironment is isolated.
- The Golden Era of Targeted PDAC: Looking past the immediate RESOLUTE-302 pan-RAS plenary drop to the fast-approaching pipelines of Claudin 18.2 combinations and MTAP-deletion / PRMT5 inhibitors.
From the immediate necessity of split-dose Cis-Gem pivots to a world where targeted pills dominate frontline care, this conversation frames the exact moment pancreatic oncology permanently moved into the precision era.
Chapters:
You can find us on X:Gut Onc Lab (@TheGutOncLab) / X
Contributors:
Dr. Nicholas Hornstein, MD, PhD, is a gastrointestinal medical oncologist and Assistant Professor Northwell Health.
Dr. Timothy Brown, MD, MSCE, is a gastrointestinal medical oncologist and Assistant Professor at UT Southwestern.
Dr. Udhayvir Grewal, MD, MBBS, is a gastrointestinal medical oncologist and Assistant Professor at Emory University School of Medicine.
Dr. Kim A. Reiss is a medical oncologist and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.